/ Biocon Sustains Trump Tamper, Up More Than 2% ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Thursday, 12 January 2017

The Indian Pharma stocks on Jan 12 were sharply hit by US President-elect Donald Trump as he hinted towards coming down hard on the lobbying in the pharma industry. Majority of the Indian Pharma companies which have operations in the US markets are trading down, however, Biocon was the only stock in the morning trade which was a gainer in the BSE Healthcare index.

S&P BSE Healthcare index as at 12.12 pm is down by 131 points. However, apart from Biocon, stocks of Opto Circuits and Aarti Drugs are also up in the range of 0.81 to 3.78%. Biocon is largely trading in green as US FDA has accepted Biologics License Application (BLA) for Mylan and Biocon's proposed biosimilar, Trastuzumab. 

The stock in the last one year has given a return of 97.47%. It is currently trading with a P/E of 26.61. The stock has outperformed the BSE Mid-cap index and the Healthcare index.
For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717